8-K: INVO Fertility Restructures Debt and Divests NAYA Therapeutics Holdings Amidst Financial Defaults and Management Change

INVO Fertility, Inc. announced a series of complex financial restructuring agreements, including the partial divestiture of its NAYA Therapeutics subsidiary, amendments to preferred stock and convertible debentures, and a key management resignation, all occurring amidst existing defaults on prior obligations.

Summary

• INVO Fertility, Inc. (the "Company") is undertaking a significant financial restructuring, including the divestiture of a majority of its holdings in NAYA Therapeutics Inc. (NTI), its wholly-owned subsidiary.
• The Company exchanged 801,196 shares (19.9% of outstanding) of NTI Class A Common Stock for 6,300 shares of NTI Series A Preferred Stock, valued at $1,000 per share and convertible at $7.86 per share.
• NTI issued a secured convertible promissory note to INVO Fertility for $4,803,175, bearing 7% annual interest and maturing on November 28, 2026, convertible upon a Qualified IPO or Sale Transaction.
• The Company amended its Series C-1 Convertible Preferred Stock, making it redeemable at the Company's option for 113.855837742504 shares of NTI Class A Common Stock per C-1 share, with a redemption notice given for May 31, 2025.
• The Series C-2 Convertible Preferred Stock was amended to increase authorized shares to 20,000 and allow dividends to be paid in Series C-2 Preferred shares, with its conversion price adjusted to $1.61 per share on May 1, 2025.
• Five Narrow Lane LP (FNL) exchanged its Series C-1 Preferred Stock for Series C-2 Preferred Stock, receiving a 15% increase in stated value and an additional 1,029 shares of Series C-2 Preferred Stock.
• FNL's existing $3,934,146 Senior Secured Convertible Debenture was exchanged for an Amended and Restated Senior Secured Convertible Debenture with a principal sum of $4,803,175, a 7% interest rate, and a maturity date of February 11, 2026.
• The Amended and Restated Debenture requires monthly redemptions of $686,167.91 plus accrued interest, commencing August 15, 2025.
• FNL was granted an Additional Investment Right to purchase up to $10,000,000 of additional Series C-2 Preferred shares, with a minimum exercise of $500,000.
• Dr. Daniel Teper resigned as President of the Company on May 28, 2025.
• The Series C-2 Preferred and Amended and Restated Debenture were issued under exemptions from registration under Sections 3(a)(9) and 4(a)(2) of the Securities Act of 1933.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the underlying reasons for the restructuring (multiple defaults, legal disputes) and the significant concessions made to debt holders, which imply substantial dilution risk for common shareholders. While the restructuring provides a framework to address immediate financial pressures and offers a potential capital raise mechanism, it stems from a position of weakness and carries high costs.

Positives

• The restructuring efforts aim to address existing financial defaults and provide a clearer path forward for the Company's debt obligations.
• The divestiture of NTI holdings may allow INVO Fertility to focus on its core business and streamline operations.
• The Amended and Restated Debenture extends the maturity date for a significant portion of debt from December 11, 2025, to February 11, 2026, providing some liquidity relief.
• The Additional Investment Right granted to FNL provides a potential source of future capital, up to $10,000,000, for the Company.
• The settlement of the 'Pritts Complaint' through a binding term sheet resolves a legal dispute that constituted a 'Triggering Event' for the Series C-2 Preferred Stock.

Negatives

• The Company has experienced multiple defaults, including 'Filing Failure' and 'Effectiveness Failure' under its Registration Rights Agreement, and 'Redemption Default' and 'Interest Default' on its prior debenture.
• The restructuring involves significant concessions to debt holders, such as the 15% increase in stated value for Series C-2 Preferred exchanged by FNL and a higher principal amount for the Amended and Restated Debenture.
• The conversion prices for preferred stock and debentures are subject to downward adjustments based on future stock performance (e.g., 85% of the arithmetic average of the three lowest VWAPs during the ten trading days prior to exercise), indicating potential for significant dilution.
• The default interest rate on the Amended and Restated Debenture is 15% per annum, which is a high penalty for non-compliance.
• The Company cannot prepay the Amended and Restated Debenture without the prior written consent of FNL, limiting financial flexibility.

Risks

• Failure to obtain stockholder approval for the issuance of common stock upon conversion of Series C-1 and C-2 Preferred Stock and the Amended and Restated Debenture could trigger further defaults or limitations.
• The Company's ability to meet the monthly redemption obligations of $686,167.91 on the Amended and Restated Debenture, commencing August 15, 2025, remains a significant liquidity risk.
• The 'Beneficial Ownership Limitation' (e.g., 4.99% for FNL's debenture, 9.99% for Series C-2 Preferred, 19.99% for NTI securities) could restrict the ability of holders to convert their securities into common stock, potentially impacting liquidity for investors.
• The 'Equity Conditions' for paying dividends in Series C-2 Preferred shares include maintaining a minimum daily trading volume of $200,000 and a VWAP exceeding the 'Floor Price' ($1.61), which could be challenging if the stock price declines.
• The Company's ongoing compliance with Nasdaq listing requirements, especially concerning public information and authorized shares, is critical to avoid further 'Events of Default' and maintain market access.
• The potential for significant dilution from the conversion of preferred stock and debentures at low conversion prices, especially with the 'Additional Investment Right' and price-based adjustments, poses a risk to existing common stockholders.

Future Outlook

The Company's future outlook is focused on navigating its restructured debt obligations and potentially leveraging the 'Additional Investment Right' for future capital. The strategic divestiture of NAYA Therapeutics Inc. holdings suggests a potential shift in business focus, though the specific implications for future operations are not detailed. The ability to meet ongoing redemption and interest payments, as well as obtain necessary stockholder approvals for conversions, will be critical for the Company's financial stability and market standing.

Management Comments

• Steven Shum, CEO, certified the Certificate of Amendment to Designation on May 28, 2025.
• Steven Shum, CEO, signed the 8-K report on May 30, 2025.

Industry Context

This filing reflects a company undergoing significant financial and structural adjustments, common in the biotechnology or medical device sectors, particularly for smaller or emerging growth companies that rely heavily on external financing. The complex nature of the preferred stock and convertible debenture terms, including anti-dilution provisions and beneficial ownership limitations, is typical for highly structured financing arrangements in these industries. The partial divestiture of a subsidiary like NAYA Therapeutics Inc. could indicate a strategic pivot or a need to streamline operations and reduce financial exposure, a trend seen in companies seeking to optimize their asset portfolios.

Comparison to Industry Standards

• The 7% interest rate on the convertible debentures and promissory notes is within a reasonable range for secured debt in the biotech/fertility industry, though the 15% default rate is on the higher end, reflecting increased risk.
• The conversion prices, particularly the adjusted $1.61 for Series C-2 Preferred and the Amended and Restated Debenture, are significantly lower than the initial conversion price of $8.2716 (adjusted) and $11.1666 (original debenture), indicating substantial dilution for existing common shareholders, which is a common outcome in distressed debt restructurings but typically worse than industry standards for healthy companies.
• The beneficial ownership limitations (e.g., 4.99% and 9.99%) are standard mechanisms to prevent a single holder from gaining too much control through conversion without triggering regulatory thresholds, aligning with typical corporate governance practices for publicly traded companies.
• The inclusion of 'Equity Conditions' for dividend payments in preferred shares, such as minimum trading volume ($200,000) and VWAP exceeding a floor price, is a common protective measure for investors in illiquid or volatile small-cap stocks, similar to terms seen in other micro-cap financing agreements.
• The requirement for stockholder approval for common stock issuance upon conversion is a standard Nasdaq listing rule (Rule 5635), ensuring compliance with exchange regulations, similar to other companies listed on Nasdaq.

Management Changes

Corporate Governance

Legal Proceedings

• A complaint was filed on May 7, 2025, by Dr. Elizabeth Pritts and the Elizabeth Pritts Revocable Living Trust against the Company and its subsidiaries (INVO Centers LLC, Wisconsin Fertility and Reproductive Surgery Associates, S.C., and Wood Violet Fertility LLC) in Wisconsin, alleging breach of contract, breach of implied covenant of good faith and fair dealing, tortious interference with contract (or veil piercing), and unjust enrichment related to various prior agreements.
• A binding term sheet was entered into on May 14, 2025, to settle all disputes related to the Pritts Complaint, which constituted a 'Triggering Event' under the Series C-2 Certificate of Designations.

Related Party Transactions

• Exchange Agreement between Naya Therapeutics, Inc. (wholly-owned subsidiary) and INVO Fertility, Inc. for NTI Class A Common Stock and NTI Series A Preferred Stock.
• NTI Secured Convertible Promissory Note issued by Naya Therapeutics, Inc. to INVO Fertility, Inc.
• Security Agreement between Naya Therapeutics, Inc. and INVO Fertility, Inc. to secure the NTI Promissory Note.
• Side Letter Agreement between Naya Therapeutics, Inc. and INVO Fertility, Inc. regarding the termination of the Security Agreement under certain conditions.
• Exchange Agreement between INVO Fertility, Inc. and GreenBlock Capital, LLC for Series C-1 Preferred Stock and Series C-2 Preferred Stock.
• Consent and Release Agreement among Decathlon Alpha V L.P., Naya Therapeutics, Inc., and INVO Fertility, Inc. regarding the release of security interests and claims.
• Consent and Release Agreement among Five Narrow Lane LP, Naya Therapeutics, Inc., and INVO Fertility, Inc. regarding the release of security interests and claims.
• Amendment and Exchange Agreement between INVO Fertility, Inc. and Five Narrow Lane LP for Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Amended and Restated Senior Secured Convertible Debenture, including an 'Additional Investment Right'.

Stakeholder Impact

• **Shareholders (Common Stockholders)**: Face significant potential dilution from the conversion of preferred stock and debentures at substantially lower conversion prices. The restructuring aims to stabilize the company, but at a cost to existing equity value.
• **Preferred Stockholders (Series C-1 & C-2)**: Series C-1 holders are subject to mandatory redemption by the Company. Series C-2 holders (like FNL and GreenBlock) have seen their terms amended, including increased authorized shares and flexible dividend payments, potentially improving their position and providing an 'Additional Investment Right' for FNL.
• **Creditors (FNL, Decathlon)**: Have agreed to new terms, including extended maturity dates and releases of security interests against NTI, in exchange for new secured notes, amended debentures with higher principal amounts, and additional investment rights, indicating a re-negotiation of their debt positions.
• **Management/Employees**: The resignation of Dr. Daniel Teper as President indicates a change in leadership, which could impact strategic direction and employee morale. The overall financial restructuring may create uncertainty but also a clearer path for the company's future.

Next Steps

• The Company will proceed with the redemption of all outstanding Series C-1 Preferred shares on May 31, 2025.
• Monthly interest payments and principal redemptions on the Amended and Restated Debenture will commence on August 15, 2025.
• The Company needs to obtain stockholder approval for the issuance of common stock upon conversion of the Series C-1 and C-2 Preferred Stock and the Amended and Restated Debenture.
• NTI's Secured Convertible Promissory Note matures on November 28, 2026, or earlier upon a Qualified IPO or Sale Transaction.
• FNL may exercise its 'Additional Investment Right' to purchase up to $10,000,000 in Series C-2 Preferred shares, with a minimum of $500,000 per exercise.

Key Dates

Recommendation

Keywords

Debt Restructuring, Convertible Debentures, Preferred Stock, SEC Filing, Corporate Governance, Risk Management, Strategic Divestiture, Financial Reporting, Capital Raise, Dilution, INVO Fertility, NAYA Therapeutics